Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737251 | 0.86 | HTR2A (0.31) | HTR2AHTR2CHTR2BCCR1CCR5 | |
| SCHEMBL6124144 | 0.84 | HSP90AB1 (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL8737765 | 0.79 | CCR1 (0.35) | HTR2ADRD2DRD3HTR2BCCR1 | |
| SCHEMBL6127805 | 0.77 | KCNA2 (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL8736924 | 0.76 | HSP90AB1 (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL30110578 | 0.74 | DRD2 (0.33) | HTR2ADRD2DRD3CCR1CCR5 | |
| SCHEMBL15688334 | 0.74 | NOS2 (0.41) | HTR2ADRD2DRD3CCR1CCR5 | |
| SCHEMBL1698415 | 0.74 | DRD2 (0.33) | HTR2ADRD2DRD3CCR1CCR5 | |
| SCHEMBL13154921 | 0.71 | PLAU (0.46) | CCR1CCR5CCR8 | |
| SCHEMBL6127826 | 0.70 | HSP90AB1 (0.35) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | HTR2A 2579/4885DRD2 4667/4885DRD3 4578/4885 |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | HTR2A 2426/4885DRD2 4498/4885DRD3 4300/4885 |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | HTR2A 2317/4885DRD2 4735/4885DRD3 4544/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | HTR2A 2307/4885DRD2 4702/4885DRD3 4499/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | HTR2A 1845/4885DRD2 4580/4885DRD3 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.